Check-Cap, which developed an ingestible capsule designed to detect early signs of colorectal cancer, plans to raise as much as $60 million in an initial public offering, according to a person familiar with the matter.
The company, whose financial backers include Pontifax Venture Capital Fund and a General Electric Co. investment arm, is in talks with investment banks for a New York listing in six to eight months, said the person, asking not to be identified because the plans aren’t public.
An executive for Check-Cap, based in Isfiya, Israel, declined to comment.
Help employers find you! Check out all the jobs and post your resume.
